There is a critical need to identify measures of cognitive functioning sensitive to early Alzheimer’s disease (AD) pathophysiology in Down syndrome to advance clinical trial research in this at-risk population. The objective of the study was to longitudinally track performance on cognitive measures in relation to neocortical and striatal amyloid beta (Aβ) in non-demented Down syndrome.
Down syndrome
New NIH-funded initiative will examine Alzheimer’s disease in people with Down syndrome
A team of researchers at the University of Wisconsin–Madison is part of a new multi-institution effort to better understand Alzheimer’s disease in adults with Down syndrome. Adults with Down syndrome are at high risk for …
Waisman BioLibrary: Down Syndrome Study
Be included! Families of children with Down syndrome are invited to participate in our new study about genetics and health. The Waisman BioLibrary is recruiting youth with Down syndrome ages 0 – 17 years. Families …
Mancheski Foundation Funds Next-Gen Research on Down Syndrome and Alzheimer’s
A gift from the Mancheski Foundation continues to provide integral support to doctoral student Matthew Zammit as he furthers his research on the progression of Alzheimer’s disease in individuals with Down syndrome. Zammit is beginning …
Lauren Bishop, PhD – Slide of the Week
We have seen a profound increase in lifespan for individuals with Down syndrome (DS) in the past few decades leading to a large and somewhat understudied population of middle- and older aged adults with DS. One health condition consistently seen in clinic-based DS samples is dementia (including Alzheimer’s disease).
In Wisconsin, 3 in 5 people with Down syndrome diagnosed with dementia by age 55
Not so many years ago, people with Down syndrome rarely survived to middle age. Many died young due to heart problems associated with the congenital condition.
Today, advances in treatment have allowed them to live longer, healthier lives.
Bradley T Christian, PhD – Slide of the Week
Individuals with Down syndrome (DS) are at increased risk of developing Alzheimer’s disease (AD) and show the earliest signs of amyloid-β (Aβ) deposition in the striatum. The metric for tracking Aβ burden using PET radiotracers frequently uses average standard uptake value ratios (SUVr) in signature regions of the brain specific to Aβ deposition.
New funding for Down syndrome research and biobank
The Waisman Center is one of 25 recipients to receive funding through a National Institutes of Health (NIH) grant that focuses on advancing research on Down syndrome. The grant is part of the NIH Investigation …
Vowel Diagnostic Treatment in Down Syndrome
The Vocal Tract Development Lab at the Waisman Center, University of Wisconsin-Madison, needs participants with Down syndrome for a pilot research study. We have developed a diagnostic treatment study designed to improve vowel production in …
Brain Imaging Study for Adults with Down Syndrome
The Waisman Center is seeking adults with Down syndrome, ages 30 and above, for a research study involving an MRI and a PET scan to examine amyloid plaque in the brains of these individuals. Researcher …